Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322448 · ClinicalTrials.gov registry record
Mechanomyography for Predictor of Prognosis in CuTS and PND Patients
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 23
- Enrollment target
NCT04322448: Completed study, sponsored by Washington University School of Medicine.
NCT04322448 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04322448 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The study will be a non-blinded two cohort design consisting only of symptomatic patients with CuTS or compressive peroneal neuropathy or in need of peroneal nerve decompression. The first cohort will be - patients with CuTS. Evaluation of each CuTS patient will include assessment by the treating surgeon and a certified hand therapist. Patients who have clinical examination and history consistent with a diagnosis of CuTS based on subjective and functional assessment outlined below will be consented to this study. The second cohort will be patients in need PND for compressive neuropathy of peroneal nerve. PND patients will be evaluated by clinical exam and have imaging with high resolution ultrasound or MRI negative for mass lesion.
Primary Outcome
PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Scores range from 0-50 with a higher indicating a better outcome.
Interventions
- DEVICE Mechanomyography (MMG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2023-02-17 |
What the finished NCT04322448 record still lists
NCT04322448 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Mechanomyography (MMG) is the first listed.
NCT04322448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04322448 about?
NCT04322448 is a clinical study titled "Mechanomyography for Predictor of Prognosis in CuTS and PND Patients". The study will be a non-blinded two cohort design consisting only of symptomatic patients with CuTS or compressive peroneal neuropathy or in need of peroneal nerve decompression. The first cohort will be - patients with CuTS. Evaluation of each CuTS patient will include assessment by the treating su...
What is the current status of trial NCT04322448?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2020-08-03. Estimated completion is 2023-02-17.
What interventions are being tested in trial NCT04322448?
The interventions under investigation include: Mechanomyography (MMG) (DEVICE).
Who is sponsoring clinical trial NCT04322448?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI